Eisai’s 2008 Eribulin NDA Plan Foiled; Beaten To The Punch By Ixempra
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)
You may also be interested in...
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.